The_DT
NF-kappa_NN
B_NN
inhibitor_NN
,_,
tepoxalin_NN
,_,
suppresses_VBZ
surface_NN
expression_NN
of_IN
the_DT
cell_NN
adhesion_NN
molecules_NNS
CD62E_NN
,_,
CD11b\/CD18_NN
and_CC
CD106_NN
._.

Tepoxalin_RB
,_,
a_DT
dual_JJ
enzyme_NN
inhibitor_NN
of_IN
cyclooxygenase_NN
and_CC
5-lipoxygenase_NN
has_VBZ
been_VBN
shown_VBN
to_TO
inhibit_VB
T-cell_NN
activation_NN
._.

Its_PRP$
immunosuppressive_JJ
property_NN
is_VBZ
distinct_JJ
from_IN
cyclosporin_NN
because_IN
only_RB
tepoxalin_NN
,_,
but_CC
not_RB
cyclosporin_NN
,_,
suppresses_VBZ
NF-kappa_NN
B_NN
activation_NN
._.

Here_RB
we_PRP
report_VBP
that_IN
tepoxalin_NN
selectively_RB
inhibits_VBZ
intercellular_JJ
adhesion_NN
molecule-1_NN
-LRB-_-LRB-
ICAM-1_NN
,_,
CD54_NN
-RRB-_-RRB-
\/_:
MAC-1_JJ
-LRB-_-LRB-
CD11b\/CD18_NN
-RRB-_-RRB-
dependent_JJ
adhesion_NN
of_IN
polymorphonuclear_JJ
cells_NNS
to_TO
IL-1_NN
activated_VBN
human_JJ
umbilical_JJ
vein_NN
endothelial_JJ
cells_NNS
._.

The_DT
mechanism_NN
of_IN
inhibition_NN
is_VBZ
related_JJ
to_TO
the_DT
surface_NN
expression_NN
of_IN
several_JJ
cell_NN
adhesion_NN
molecules_NNS
._.

Flow_NN
cytometry_NN
analyses_NNS
on_IN
cultured_VBN
cells_NNS
that_WDT
were_VBD
treated_VBN
with_IN
tepoxalin_NN
or_CC
antisense_JJ
oligonucleotides_NNS
to_TO
the_DT
P65\/p50_NN
subunit_NN
of_IN
NF-kappa_NN
B_NN
,_,
and_CC
then_RB
stimulated_VBN
with_IN
PMA_NN
,_,
revealed_VBD
a_DT
reduced_VBN
expression_NN
of_IN
CD11b\/CD18_NN
on_IN
monocytic_JJ
HL60_NN
cells_NNS
,_,
and_CC
endothelial_JJ
adhesion_NN
molecule-1_NN
-LRB-_-LRB-
CD62E_NN
-RRB-_-RRB-
and_CC
vascular_JJ
adhesion_NN
molecule-1_NN
-LRB-_-LRB-
CD106_NN
-RRB-_-RRB-
on_IN
human_JJ
umbilical_JJ
vein_NN
endothelial_JJ
cells_NNS
._.

Expression_NN
of_IN
other_JJ
adhesion_NN
molecules_NNS
such_JJ
as_IN
lymphocyte_NN
function_NN
associated-antigen-1_NN
-LRB-_-LRB-
CD11a\/CD18_NN
-RRB-_-RRB-
and_CC
CD54_NN
were_VBD
unaffected_JJ
._.

Tepoxalin_NN
also_RB
inhibited_VBD
the_DT
secretion_NN
of_IN
a_DT
NF-kappa_NN
B_NN
regulated_JJ
chemokine_NN
,_,
IL-8_NN
,_,
a_DT
known_JJ
inducer_NN
of_IN
CD11b\/CD18_NN
expression_NN
._.

Thus_RB
the_DT
suppression_NN
of_IN
CD11b\/CD18_NN
expression_NN
by_IN
tepoxalin_NN
may_MD
involve_VB
IL-8_NN
._.

Our_PRP$
results_NNS
suggest_VBP
that_IN
by_IN
inhibiting_VBG
NF-kappa_NN
B_NN
activation_NN
,_,
surface_NN
expression_NN
of_IN
several_JJ
adhesion_NN
molecules_NNS
can_MD
be_VB
modulated_VBN
and_CC
that_IN
tepoxalin_NN
may_MD
be_VB
useful_JJ
in_IN
treating_VBG
selected_VBN
adhesion_NN
mediated_JJ
events_NNS
such_JJ
as_IN
leukocyte_NN
migration_NN
or_CC
atherosclerotic_JJ
plaque_NN
formation_NN
._.

